Background {#Sec1}
==========

A 2014 systematic review suggests that the positive predictive value (PPV) for cancer is 33% in patients with an unexpected 10% loss of weight from baseline over 6--12 months. The same review reported a wide range of differential diagnoses for patients with unexpected weight loss, including advanced heart failure, chronic obstructive pulmonary disease, renal disease, pancreatic insufficiency, malabsorption, and endocrine disease, with up to 25% of patients without a diagnosis to explain their weight loss after extended follow-up \[[@CR1]\]. However, these data mainly come from hospital inpatient populations or patients referred to the outpatient clinic where the prevalence of cancer and serious disease is much higher than in primary care as GPs have already filtered out many cases of weight loss that are more likely to be attributable to another cause. Given the absence of appropriate clinical guidelines or standardised practice, clinicians have been reported to take a wide range of action in response to patients with unexpected weight loss, from doing nothing through to ordering "extensive blind investigations" because of the fear of underlying cancer \[[@CR2]\].

On the basis of primary care research, NICE (2015) has since suggested that unexpected weight loss is a sign of seven cancers, citing evidence from 14 studies reporting positive predictive values (PPVs) of 0.4--3% \[[@CR3]\]. The problem for GPs is how to interpret and implement the term weight loss in these cancer guidelines: NICE do not define the degree of weight loss, or the time period of loss, that should prompt referral. Most cited studies referred to in the NICE guidelines define weight loss on the basis of a coded entry in the GP record, often based on a report of weight loss (volunteered by, or elicited from, the patient) rather than measured weight change \[[@CR4]--[@CR6]\]. Only one study referred to by NICE quantified the degree of weight loss that predicts colorectal cancer in primary care reporting odds ratios of 1.2 (95% CI 0.99--1.5) for 5--9.9% and 2.5 (2.1--3) for ≥ 10% weight loss \[[@CR7]\]. However, in this study, weight loss was defined by comparing the last recorded weight with the highest recorded weight in the preceding 2 years \[[@CR7]\], as weight is not routinely recorded in primary care and is considered a common missing variable in primary care databases \[[@CR8]\].

There is an evidence gap for a comprehensive study to describe the use of weight measurement and coding for unexpected weight loss in primary care and for a study that determines the association between unexpected weight loss and cancer and serious disease that may lead to a comprehensive recommendation for the investigation of unexpected weight loss in primary care.

Objective {#Sec2}
=========

The overall objective is to provide the evidence necessary to allow GPs to more effectively manage unexpected weight loss.

Aims and rationale {#Sec3}
------------------

### Aim 1.1 {#FPar1}

To describe how often and when weight is measured, and the symptom of unexpected weight loss recorded as a code, in adults aged \> 18 years, in NHS primary care.

### Aim 1.2 {#FPar2}

To describe what action is taken in response to unexpected weight loss, in adults aged \> 18 years, in NHS primary care.

Weight measurements and weight loss codes will be categorised using a rule-based search strategy developed as part of this project to identify the clinical purpose and clinical condition related to each weight entry in the primary care record, and the investigations requested, medications prescribed, and referrals made in response to the symptom of weight loss.

### Aim 2.1 {#FPar3}

To identify the predictive value of unexpected weight loss recorded as a symptom for cancer in primary care in adults aged \> 18 years.

### Aim 2.2 {#FPar4}

If the symptom of unexpected weight loss predicts cancer, to explore if it is (i) independent of other symptoms, signs, and test results and (ii) restricted to late-stage disease.

### Aim 2.3 {#FPar5}

To ascertain the predictive value of unexpected weight loss recorded as a symptom for serious disease in primary care.

The evidence regarding the predictive value of unexpected weight loss for cancer in primary care, which underpins the 2015 NICE guideline, does not cover all cancer types or take cancer stage at diagnosis into account. We will identify the predictive value of unexpected weight loss in primary care across all cancer types, explore the incremental predictive value of symptom combinations, and examine the association with cancer stage at diagnosis using a matched open cohort study design. In cases where cancer is excluded, an understanding of which alternative diagnoses are related to unexpected weight loss will inform subsequent management decisions in primary care. We will therefore identify the disease groups for which unexpected weight loss is also predictive to develop clinical guidance for the investigation of unexpected weight loss in primary care.

Study type {#Sec4}
==========

Aim 1: Descriptive {#Sec5}
------------------

The descriptive epidemiology of weight measurement and weight loss coding in NHS primary care.

Aims 2.1 and 2.3: Hypothesis testing {#Sec6}
------------------------------------

A cohort study of weight loss as a sign of cancer and serious disease in NHS primary care.

Aim 2.2: Exploratory {#Sec7}
--------------------

Exploratory analysis to investigate the influence of covariates on the relationship between weight loss and the occurrence of cancer and serious disease.

Study design {#Sec8}
============

The design of the study is an open cohort study. {#Sec9}
------------------------------------------------

Sample size {#Sec10}
===========

In preparing this ISAC application, a preliminary search of 20 GP practices from 2000 to 2013 was conducted. Of 127,024 patients \> 40 years with acceptable records, 80,562 (63.4%) had at least one weight measurement recorded during that period, 30,728 (24.1%) had two weight measurements within 6 months of each other, and 40,436 (31.8%) within 1 year; 3079 (2.4%) of patients had a Read code for weight loss but only half of these had an accompanying weight measurement.

Two thousand one hundred eighty-four patients with weight loss are required to detect a hazard ratio of 2 (a change in incidence of 1.5 to 3%) at 99% power (0.05% alpha) using a ratio of one case to five controls. It is anticipated that the study will therefore have sufficient power for stratification by cancer type, cancer stage, and using symptom combinations even though linkage to cancer registry may only be possible in approximately 60% of cancer cases \[[@CR9]\].

Preliminary work in Clinical Practice Research Datalink (CPRD) estimated that that unexpected weight loss is coded as a symptom for about approximately 148,000 patients \> 18 years and is distributed evenly across decades of age providing adequate statistical power and precision for a comprehensive cohort study investigating cancer and serious disease in adults (\> 18 years). For example, if 3% of patients with weight loss develop cancer the number of Events Per Variable will far exceed the minimum number required for robust statistical modelling.

Data linkage {#Sec11}
============

NCDR Cancer Registry Data {#FPar6}
-------------------------

Linkage to the cancer register is required as cancer is a major outcome variable in this cohort study. Cancer registry data will provide more accurate information on cancer site and stage than reliance on the primary care record.

Office of National Statistics (ONS) mortality data {#FPar7}
--------------------------------------------------

Linkage is required to cross-validate cause of death for patients confirmed to have died of cancer using Cancer Registry Data linkage and to identify or confirm the cause of death in patients with and without serious disease as identified by the GP record.

Index of Multiple Deprivation (IMD) scores {#FPar8}
------------------------------------------

They are required to provide a GP (and where possible patient) level proxy for socioeconomic status to be used when describing both the baseline characteristics in the descriptive analysis of Aim 1 and the cohort analysis of Aim 2. IMD score will also be used as a covariate in the multivariate cox regression analysis as part of Aim 2 (see below).

Study population {#Sec12}
================

The study population is summarised in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flowchart of study populations

Aim 1: Descriptive study {#FPar9}
------------------------

NHS patients \> 18 yearsRegistered with a GP practice 1 January 2000--31 December 2011Eligible for data linkage with Cancer registry and ONS data

Aim 2: Cohort analysis {#FPar10}
----------------------

Inclusions:NHS patients \> 18 yearsRegistered with a GP practice 1 January 2000--31 December 2011Eligible for data linkage with Cancer registry and ONS data.Patients with one of the unexpected weight loss codes (defined in Table [1](#Tab1){ref-type="table"})Table 1Weight measurement and unexpected weight loss codesUnexpected weight loss codesMedcodeReadcodeReadterm12622A6.00O/E---underweight6541623Weight decreasing1581162..00Weight symptom3647R032.00\[D\]Abnormal loss of weight46631625Abnormal weight loss58121625.11Abnormal weight loss---symptom12,3981D1A.00Complaining of weight loss12,530R034800\[D\]Underweight14,764162Z.00Weight symptom NOS22,0052224O/E---cachexic24,068R2y4.00\[D\]Cachexia32,91422K3.00Body Mass Index low K/M237,93722A8.00Weight loss from baseline weight42,30922A7.00Baseline weight53,801R2y4z00\[D\]Cachexia NOS102,5631627Unintentional weight lossWeight measurement codes222A..00O/E---weight810522K..00Body mass index901522K4.00Body mass index 25--29---overweight13,27822K5.00Body mass index 30+---obesity21,52022AZ.00O/E---weight NOS22,55622K7.00Body mass index 40+---severely obese24,49622K6.00Body mass index less than 2028,93722K2.00Body mass index high K/M228,94622K1.00Body mass index normal K/M244,29122K8.00Body mass index 20--24---normal101,04722K9.00Body mass index centile105,79122K9000Baseline body mass index centile105,80022KB.00Baseline body mass index107,23122KA.00Target body mass index

Exclusions:Patients with a diagnosis of cancer prior to the index symptom of weight loss.

Selection of comparison group(s) or controls {#Sec13}
============================================

Aim 1: Descriptive study {#Sec14}
------------------------

-No comparison group is required.

Aim 2: Cohort analysis {#Sec15}
----------------------

A matched cohort of patients without weight loss---patients without a coded entry for weight loss will be matched for age and sex and selected from the population of patients registered with the same practice having consulted within ± 3 months of the index weight loss code.Matching for age and sex will ensure there are sufficient patients without weight loss in each age and sex strata.A 1:5 sampling ratio achieves the best balance between data cost and statistical power (see sample size).

Exposures, outcomes and covariates {#Sec16}
==================================

Aim 1: Descriptive study {#Sec17}
------------------------

Outcome 1: Objective weight measurement---quantitative weight measurements.

Outcome 2: Weight loss code---Read Codes defined in Table [1](#Tab1){ref-type="table"}.

Patients with objective weight measurements or the symptom of unexpected weight loss recorded using the following Medcodes and Read codes listed in Table [1](#Tab1){ref-type="table"}.

Aim 2: Cohort analysis {#Sec18}
----------------------

### Exposure---weight loss {#Sec19}

Patients with the symptom of weight loss recorded using the unexpected weight loss Medcodes and Read Codes listed in Table [1](#Tab1){ref-type="table"}. Weight loss codes will be independently categorised for clinical relavence by four co-investigators based on the results of the descriptive analysis, then consensus reached through discussion.   

### Outcome---cancer {#Sec20}

A library of over 1600 Read Codes and ICD-10 codes (grouped by site---see Table [2](#Tab2){ref-type="table"}) developed by Hamilton and colleagues will be reviewed, updated using Read Code searches, and validated through consensus amongst co-investigators. All new cancer diagnoses in the 24 months following the weight loss code will be identified in CPRD and linked cancer registry data. To inform this analysis, data will also be extracted on cancer stage, grade, tumour size, and histology at diagnosis.Table 2Cancer codesCancerRead codeDescriptionMedcodeICD 10BladderB490.00Malignant neoplasm of trigone of urinary bladder38,862C670B491.00Malignant neoplasm of dome of urinary bladder44,996C671B492.00Malignant neoplasm of lateral wall of urinary bladder35,963C672B493.00Malignant neoplasm of anterior wall of urinary bladder19,162C673B494.00Malignant neoplasm of posterior wall of urinary bladder42,012C674B495.00Malignant neoplasm of bladder neck41,571C675B496.00Malignant neoplasm of ureteric orifice28,241C676B497.00Malignant neoplasm of urachus42,023C677B49y000Malignant neoplasm, overlapping lesion of bladder47,801C678B49y.00Malignant neoplasm of other site of urinary bladder36,949C679B49z.00Malignant neoplasm of urinary bladder NOS31,102C679BreastB335200Malignant neoplasm of skin of breast30,543C445B34..11CA female breast348C50B34..00Malignant neoplasm of female breast3968C50B340000Malignant neoplasm of nipple of female breast23,380C500B340.00Malignant neoplasm of nipple and areola of female breast26,853C500B340z00Malignant neoplasm of nipple or areola of female breast nos59,831C500B340100Malignant neoplasm of areola of female breast64,686C500B341.00Malignant neoplasm of central part of female breast31,546C501B342.00Malignant neoplasm of upper-inner quadrant of female breast29,826C502B343.00Malignant neoplasm of lower-inner quadrant of female breast45,222C503B344.00Malignant neoplasm of upper-outer quadrant of female breast23,399C504B345.00Malignant neoplasm of lower-outer quadrant of female breast42,070C505B346.00Malignant neoplasm of axillary tail of female breast20,685C506B34y000Malignant neoplasm of ectopic site of female breast95,057C508B34yz00Malignant neoplasm of other site of female breast nos38,475C509B34y.00Malignant neoplasm of other site of female breast56,715C509B34z.00Malignant neoplasm of female breast nos9470C509CervixB410z00Malignant neoplasm of endocervix nos50,285C530B410.00Malignant neoplasm of endocervix48,820C530B410000Malignant neoplasm of endocervical canal57,235C530B410100Malignant neoplasm of endocervical gland53,103C530B411.00Malignant neoplasm of exocervix50,297C531B412.00Malignant neoplasm, overlapping lesion of cervix uteri58,094C538B41y100Malignant neoplasm of squamocolumnar junction of cervix57,719C538B41y000Malignant neoplasm of cervical stump95,505C538B41yz00Malignant neoplasm of other site of cervix nos43,435C539B41z.00Malignant neoplasm of cervix uteri nos28,311C539B41y.00Malignant neoplasm of other site of cervix32,955C539ColorectalB134.11Carcinoma of caecum22,163C180B134.00Malignant neoplasm of caecum3811C180B136.00Malignant neoplasm of ascending colon10,946C182B130.00Malignant neoplasm of hepatic flexure of colon9088C183B131.00Malignant neoplasm of transverse colon6935C184B137.00Malignant neoplasm of splenic flexure of colon18,619C185B132.00Malignant neoplasm of descending colon10,864C186B133.00Malignant neoplasm of sigmoid colon2815C187B138.00Malignant neoplasm, overlapping lesion of colon93,478C188B13y.00Malignant neoplasm of other specified sites of colon48,231C189B13z.11Colonic cancer9118C189B13z.00Malignant neoplasm of colon nos28,163C189B140.00Malignant neoplasm of rectosigmoid junction27,855C19B141.12Rectal carcinoma5901C20B141.11Carcinoma of rectum7219C20B141.00Malignant neoplasm of rectum1800C20B14y.00Malig neop other site rectum, rectosigmoid junction and anus55,659C218B14z.00Malignant neoplasm rectum,rectosigmoid junction and anus nos50,974C218B1z0.11Cancer of bowel11,628C260B18y200Malignant neoplasm of mesorectum30,165C481LarynxB214.00Malignant neoplasm, overlapping lesion of larynx50,579C328B21z.00Malignant neoplasm of larynx NOS9237C329B21y.00Malignant neoplasm of larynx, other specified site26,813C329B210.00Malignant neoplasm of glottis318C320B215.00Malignant neoplasm of epiglottis NOS55,374C321B211.00Malignant neoplasm of supraglottis26,165C321B212.00Malignant neoplasm of subglottis22,441C322B213z00Malignant neoplasm of laryngeal cartilage NOS97,332C323B213000Malignant neoplasm of arytenoid cartilage63,460C323B213.00Malignant neoplasm of laryngeal cartilage43,111C323B213100Malignant neoplasm of cricoid cartilage37,805C323ThyroidB213300Malignant neoplasm of thyroid cartilage47,862C323B53..00Malignant neoplasm of thyroid gland5637C73SarcomaB150200Primary angiosarcoma of liver68,410C223B1z1100Fibrosarcoma of spleen72,224C261B30z000Osteosarcoma19,437C419B339.00Dermatofibrosarcoma protuberans24,375C449B33z000Kaposi's sarcoma of skin27,931C460B05z000Kaposi's sarcoma of palate37,549C462B6z0.00Kaposi's sarcoma of lymph nodes50,290C463B592X00Kaposi's sarcoma of multiple organs65,466C468Byu5300\[X\]kaposi's sarcoma, unspecified93,665C469B59zX00Kaposi's sarcoma, unspecified49,525C469B600000Reticulosarcoma of unspecified site60,242C833B600100Reticulosarcoma of lymph nodes of head, face, and neck71,031C833B600700Reticulosarcoma of spleen95,058C833B600300Reticulosarcoma of intra-abdominal lymph nodes70,374C833B600.00Reticulosarcoma1481C839B601000Lymphosarcoma of unspecified site71,625C850B601200Lymphosarcoma of intrathoracic lymph nodes62,380C850B601.00Lymphosarcoma27,416C850B601100Lymphosarcoma of lymph nodes of head, face and neck71,238C850B601z00Lymphosarcoma nos63,723C850B601300Lymphosarcoma of intra-abdominal lymph nodes64,670C850B653.00Myeloid sarcoma70,724C923B653100Granulocytic sarcoma39,629C923B67y000Lymphosarcoma cell leukaemia72,197C947B304200Malignant neoplasm of humerus61,741C400B304000Malignant neoplasm of scapula49,054C400B304300Malignant neoplasm of radius92,371C400B304.00Malignant neoplasm of scapula and long bones of upper arm71,810C400B304z00Malignant neoplasm of scapula and long bones of upper arm NOS65,880C400B304400Malignant neoplasm of ulna64,848C400B305.00Malignant neoplasm of hand bones73,530C401B305.12Malignant neoplasm of metacarpal bones72,464C401B305C00Malignant neoplasm of fifth metacarpal bone94,427C401B305z00Malignant neoplasm of hand bones NOS73,556C401B305100Malignant neoplasm of carpal bone---lunate69,104C401B305000Malignant neoplasm of carpal bone---scaphoid57,988C401B305D00Malignant neoplasm of phalanges of hand86,812C401B307z00Malignant neoplasm of long bones of leg NOS62,630C402B307.00Malignant neoplasm of long bones of leg68,055C402B307200Malignant neoplasm of tibia40,814C402B307100Malignant neoplasm of fibula50,402C402B307000Malignant neoplasm of femur56,513C402B308300Malignant neoplasm of medial cuneiform34,878C403B308800Malignant neoplasm of first metatarsal bone69,927C403B308B00Malignant neoplasm of fourth metatarsal bone92,382C403B308100Malignant neoplasm of talus95,182C403B308D00Malignant neoplasm of phalanges of foot58,949C403B308200Malignant neoplasm of calcaneum72,212C403B30X.00Malignant neoplasm/bones + articular cartilage/limb, unspecified43,614C409Byu3100\[X\]Malignant neoplasm/bones + articular cartilage/limb, unspecified73,296C409B300600Malignant neoplasm of parietal bone54,747C410B300400Malignant neoplasm of occipital bone55,953C410B300z00Malignant neoplasm of bones of skull and face NOS69,146C410B300300Malignant neoplasm of nasal bone95,458C410B300900Malignant neoplasm of zygomatic bone50,299C410B300C00Malignant neoplasm of vomer44,452C410B300500Malignant neoplasm of orbital bone50,298C410B300700Malignant neoplasm of sphenoid bone55,595C410B300200Malignant neoplasm of malar bone59,520C410B300B00Malignant neoplasm of turbinate96,445C410B300000Malignant neoplasm of ethmoid bone53,594C410B300100Malignant neoplasm of frontal bone53,599C410B300800Malignant neoplasm of temporal bone62,104C410B300.00Malignant neoplasm of bones of skull and face59,036C410B300A00Malignant neoplasm of maxilla17,475C410B301.00Malignant neoplasm of mandible33,833C411B302100Malignant neoplasm of thoracic vertebra32,372C412B302.00Malignant neoplasm of vertebral column16,704C412B302000Malignant neoplasm of cervical vertebra46,939C412B302200Malignant neoplasm of lumbar vertebra54,691C412B302z00Malignant neoplasm of vertebral column NOS49,701C412B303000Malignant neoplasm of rib37,842C413B303.00Malignant neoplasm of ribs, sternum and clavicle27,528C413B303100Malignant neoplasm of sternum49,491C413B303z00Malignant neoplasm of rib, sternum and clavicle NOS51,237C413B303500Malignant neoplasm of xiphoid process54,493C413B303300Malignant neoplasm of costal cartilage60,403C413B303200Malignant neoplasm of clavicle66,639C413B306.00Malignant neoplasm of pelvic bones, sacrum and coccyx54,631C414B306100Malignant neoplasm of ischium59,223C414B306400Malignant neoplasm of coccygeal vertebra66,908C414B306z00Malignant neoplasm of pelvis, sacrum or coccyx NOS38,938C414B306300Malignant neoplasm of sacral vertebra40,966C414B306200Malignant neoplasm of pubis51,921C414B306000Malignant neoplasm of ilium44,609C414Byu3200\[X\]Malignant neoplasm/overlap lesion/bone + articular cartilage63,300C418B30W.00Malignant neoplasm/overlap lesion/bone + articular cartilage67,451C418B303400Malignant neoplasm of costo-vertebral joint67,763C418B30z.00Malignant neoplasm of bone and articular cartilage NOS16,075C419Byu3300\[X\]Malignant neoplasm/bone + articular cartilage, unspecified43,151C419B310z00Malig neop connective and soft tissue head, face, neck NOS73,718C490B310100Malignant neoplasm of soft tissue of face40,014C490B310000Malignant neoplasm of soft tissue of head59,382C490B310300Malignant neoplasm of cartilage of ear60,035C490B310.00Malignant neoplasm of connective and soft tissue head, face and neck43,475C490B310200Malignant neoplasm of soft tissue of neck48,517C490B310400Malignant neoplasm of tarsus of eyelid49,463C490B311500Malignant neoplasm of connective and soft tissue of thumb63,988C491B311200Malignant neoplasm of connective and soft tissue of fore-arm57,482C491B311100Malignant neoplasm of connective and soft tissue, upper arm64,345C491B311000Malignant neoplasm of connective and soft tissue of shoulder50,222C491B311400Malignant neoplasm of connective and soft tissue of finger91,586C491B311300Malignant neoplasm of connective and soft tissue of hand19,321C491B311.00Malignant neoplasm connective and soft tissue upper limb/shoulder53,989C491B312300Malignant neoplasm of connective and soft tissue of lower leg30,542C492B312400Malignant neoplasm of connective and soft tissue of foot54,222C492B312.00Malignant neoplasm of connective and soft tissue of hip and leg66,088C492B312z00Malignant neoplasm connective and soft tissue hip and leg NOS90,546C492B312200Malignant neoplasm connective and soft tissue of popliteal space54,965C492B312100Malignant neoplasm of connective and soft tissue thigh and upper leg44,805C492B313100Malignant neoplasm of diaphragm54,186C493B313.00Malignant neoplasm of connective and soft tissue of thorax22,290C493B313000Malignant neoplasm of connective and soft tissue of axilla29,160C493B313200Malignant neoplasm of great vessels72,522C493B314.00Malignant neoplasm of connective and soft tissue of abdomen45,071C494B314z00Malignant neoplasm of connective and soft tissue of abdomen NOS60,247C494B314000Malignant neoplasm of connective and soft tissue of abdominal wall66,488C494B315z00Malignant neoplasm of connective and soft tissue of pelvis NOS58,836C495B315000Malignant neoplasm of connective and soft tissue of buttock70,463C495B315200Malignant neoplasm of connective and soft tissue of perineum59,152C495B315.00Malignant neoplasm of connective and soft tissue of pelvis51,965C495B315100Malignant neoplasm of connective and soft tissue of inguinal region67,324C495Byu5800\[X\]Mal neoplasm/connective + soft tissue of trunk, unspecified91,896C496B314100Malig neoplasm of connective and soft tissues of lumb spine94,272C496B316.00Malig neop of connective and soft tissue trunk unspecified57,471C496B31z.00Malignant neoplasm of connective and soft tissue, site NOS15,182C499Byu5900\[X\]Malignant neoplasm/connective + soft tissue, unspecified91,457C499B31y.00Malignant neoplasm connective and soft tissue other specified site65,233C499KidneyB4A0.00Malignant neoplasm of kidney parenchyma1599C64B4A..11Renal malignant neoplasm18,712C64B4A..00Malignant neoplasm of kidney and other unspecified urinary organs13,559C64B4A0000Hypernephroma7978C64B4A1000Malignant neoplasm of renal calyces27,540C65B4A1z00Malignant neoplasm of renal pelvis NOS54,184C65B4A1.00Malignant neoplasm of renal pelvis12,389C65B4Az.00Malignant neoplasm of kidney or urinary organs NOS29,462C689LungB221100Malignant neoplasm of hilus of lung33,444C340B221.00Malignant neoplasm of main bronchus12,870C340B221z00Malignant neoplasm of main bronchus NOS21,698C340B221000Malignant neoplasm of carina of bronchus17,391C340B222.11Pancoast's syndrome20,170C341B222.00Malignant neoplasm of upper lobe, bronchus or lung10,358C341B222000Malignant neoplasm of upper lobe bronchus31,700C341B222100Malignant neoplasm of upper lobe of lung25,886C341B222z00Malignant neoplasm of upper lobe, bronchus or lung NOS44,169C341B223100Malignant neoplasm of middle lobe of lung39,923C342B223z00Malignant neoplasm of middle lobe, bronchus or lung NOS54,134C342B223.00Malignant neoplasm of middle lobe, bronchus or lung31,268C342B223000Malignant neoplasm of middle lobe bronchus41,523C342B224z00Malignant neoplasm of lower lobe, bronchus or lung NOS42,566C343B224100Malignant neoplasm of lower lobe of lung12,582C343B224000Malignant neoplasm of lower lobe bronchus18,678C343B224.00Malignant neoplasm of lower lobe, bronchus or lung31,188C343B225.00Malignant neoplasm of overlapping lesion of bronchus and lung36,371C348B22z.00Malignant neoplasm of bronchus or lung NOS3903C349Byu2000\[X\]malignant neoplasm of bronchus or lung, unspecified40,595C349B22z.11Lung cancer2587C349B22y.00Malignant neoplasm of other sites of bronchus or lung38,961C349B26..00Malignant neoplasm, overlap lesion of resp and intrathor orgs66,646C398B2zy.00Malignant neoplasm of other site of respiratory tract29,283C399Hodgkins lymphomaB613.00Hodgkin's disease, lymphocytic-histiocytic predominance38,939C810B613600Hodgkin's, lymphocytic-histiocytic pred intrapelvic nodes95,338C810B613z00Hodgkin's, lymphocytic-histiocytic predominance nos29,876C810B613300Hodgkin's, lymphocytic-histiocytic pred intra-abdominal node73,532C810B613000Hodgkin's, lymphocytic-histiocytic predominance unspec site71,142C810B613200Hodgkin's, lymphocytic-histiocytic pred intrathoracic nodes92,245C810B613100Hodgkin's, lymphocytic-histiocytic pred of head, face, neck68,330C810B613500Hodgkin's, lymphocytic-histiocytic pred inguinal and leg93,951C810B614400Hodgkin's nodular sclerosis of lymph nodes of axilla and arm65,483C811B614300Hodgkin's nodular sclerosis of intra-abdominal lymph nodes61,149C811B614.00Hodgkin's disease, nodular sclerosis29,178C811B614100Hodgkin's nodular sclerosis of head, face and neck55,303C811B614z00Hodgkin's disease, nodular sclerosis NOS63,054C811B614200Hodgkin's nodular sclerosis of intrathoracic lymph nodes67,506C811B614000Hodgkin's disease, nodular sclerosis of unspecified site57,225C811B614800Hodgkin's nodular sclerosis of lymph nodes of multiple sites19,140C811B615200Hodgkin's mixed cellularity of intrathoracic lymph nodes58,684C812B615z00Hodgkin's disease, mixed cellularity NOS94,005C812B615.00Hodgkin's disease, mixed cellularity49,605C812B615100Hodgkin's mixed cellularity of lymph nodes head, face, neck94,407C812B615000Hodgkin's disease, mixed cellularity of unspecified site97,863C812B616.00Hodgkin's disease, lymphocytic depletion67,703C813B616400Hodgkin's lymphocytic depletion lymph nodes axilla and arm63,625C813B616000Hodgkin's lymphocytic depletion of unspecified site95,049C813ByuD000\[X\]other Hodgkin's disease43,415C817B610.00Hodgkin's paragranuloma65,489C817B611.00Hodgkin's granuloma44,196C817B61z100Hodgkin's disease NOS of lymph nodes of head, face and neck59,778C819B61..00Hodgkin's disease2462C819B61zz00Hodgkin's disease NOS42,461C819B61z800Hodgkin's disease NOS of lymph nodes of multiple sites97,746C819B61z200Hodgkin's disease NOS of intrathoracic lymph nodes59,755C819B61z.00Hodgkin's disease NOS53,397C819B61z000Hodgkin's disease NOS, unspecified site61,662C819B61z400Hodgkin's disease NOS of lymph nodes of axilla and arm91,900C819B61z700Hodgkin's disease NOS of spleen94,279C819B612.00Hodgkin's sarcoma64,036C817B612400Hodgkin's sarcoma of lymph nodes of axilla and upper limb68,039C817Non-Hodgkins lymphomaB627000Follicular non-Hodgkin's small cleaved cell lymphoma28,639C820B627100Follicular non-Hodgkin's mixed sml cleavd & lge cell lymphoma70,842C821B627200Follicular non-Hodgkin's large cell lymphoma49,262C822B627B00Other types of follicular non-Hodgkin's lymphoma31,576C827ByuD100\[X\]other types of follicular non-Hodgkin's lymphoma67,518C827B620500Nodular lymphoma of lymph nodes of inguinal region and leg94,995C829B627C11Follicular lymphoma NOS17,182C829B620000Nodular lymphoma of unspecified site66,327C829B620100Nodular lymphoma of lymph nodes of head, face and neck45,264C829B620z00Nodular lymphoma NOS65,701C829B620.00Nodular lymphoma (brill - symmers disease)5179C829B620300Nodular lymphoma of intra-abdominal lymph nodes92,068C829B627C00Follicular non-Hodgkin's lymphoma21,549C829B620800Nodular lymphoma of lymph nodes of multiple sites58,082C829B627300Diffuse non-Hodgkin's small cell (diffuse) lymphoma50,668C830B627500Diffuse non-Hodgkin mixed small & large cell (diffuse) lymphoma50,695C832B627600Diffuse non-Hodgkin's immunoblastic (diffuse) lymphoma53,551C834B627700Diffuse non-Hodgkin's lymphoblastic (diffuse) lymphoma17,460C835B627800Diffuse non-Hodgkin's lymphoma undifferentiated (diffuse)65,180C836B602300Burkitt's lymphoma of intra-abdominal lymph nodes97,577C837B602z00Burkitt's lymphoma NOS71,304C837B602.00Burkitt's lymphoma21,402C837B602500Burkitt's lymphoma of lymph nodes of inguinal region and leg92,380C837B602100Burkitt's lymphoma of lymph nodes of head, face and neck59,115C837B627D00Diffuse non-Hodgkin's centroblastic lymphoma70,509C838ByuDC00\[X\]Diffuse non-Hodgkin's lymphoma, unspecified64,515C839B627X00Diffuse non-Hodgkin's lymphoma, unspecified39,798C839B622.00Sezary's disease35,014C841B62x000T-zone lymphoma90,201C842B62x100Lymphoepithelioid lymphoma57,737C843B62x200Peripheral t-cell lymphoma12,464C844B62xX00Oth and unspecif peripheral and cutaneous t cell lymphomas44,318C845B627W00Unspecified b-cell non-Hodgkin's lymphoma31,794C851ByuDE00\[X\]unspecified b-cell non-Hodgkin's lymphoma63,375C851ByuD300\[X\]Other specified types of non-Hodgkin's lymphoma64,336C857B62y100Malignant lymphoma NOS of lymph nodes of head, face and neck50,696C859B62y500Malignant lymphoma NOS of lymph node inguinal region and leg63,105C859B62y400Malignant lymphoma NOS of lymph nodes of axilla and arm34,089C859B62y000Malignant lymphoma NOS of unspecified site57,427C859B62y700Malignant lymphoma NOS of spleen60,092C859ByuDF11\[X\]Non-Hodgkin's lymphoma NOS7940C859B62y600Malignant lymphoma NOS of intrapelvic lymph nodes71,262C859B62y200Malignant lymphoma NOS of intrathoracic lymph nodes72,725C859B62yz00Malignant lymphoma NOS15,027C859ByuDF00\[X\]Non-Hodgkin's lymphoma, unspecified type8649C859B62y.00Malignant lymphoma NOS12,335C859B62y300Malignant lymphoma NOS of intra-abdominal lymph nodes42,579C859B62x600True histiocytic lymphoma95,630C963B6z..00Malignant neoplasm lymphatic or haematopoietic tissue NOS49,301C969B62y800Malignant lymphoma NOS of lymph nodes of multiple sites15,504C969B621000Mycosis fungoides of unspecified site95,949C840B621500Mycosis fungoides of lymph nodes of inguinal region and leg72,714C840B621.00Mycosis fungoides12,006C840B621800Mycosis fungoides of lymph nodes of multiple sites95,012C840B621400Mycosis fungoides of lymph nodes of axilla and upper limb96,379C840B621300Mycosis fungoides of intra-abdominal lymph nodes91,674C840B621z00Mycosis fungoides NOS38,005C840B62x400Malignant reticulosis62,437C857MelanomaB320.00Malignant melanoma of lip70,637C430B321.00Malignant melanoma of eyelid including canthus54,632C431B322000Malignant melanoma of auricle (ear)59,061C432B322.00Malignant melanoma of ear and external auricular canal57,260C432B322z00Malignant melanoma of ear and external auricular canal NOS73,744C432B323100Malignant melanoma of chin71,136C433B323200Malignant melanoma of eyebrow47,094C433B323500Malignant melanoma of temple58,958C433B323z00Malignant melanoma of face NOS67,806C433Byu4000\[X\]malignant melanoma of other + unspecified parts of face56,925C433B323.00Malignant melanoma of other and unspecified parts of face47,252C433B323300Malignant melanoma of forehead68,133C433B323400Malignant melanoma of external surface of nose45,139C433B323000Malignant melanoma of external surface of cheek41,278C433B324000Malignant melanoma of scalp55,881C434B324.00Malignant melanoma of scalp and neck65,625C434B324100Malignant melanoma of neck45,306C434B325700Malignant melanoma of back43,463C435B325800Malignant melanoma of chest wall51,209C435B325600Malignant melanoma of umbilicus43,715C435B325100Malignant melanoma of breast32,768C435B325300Malignant melanoma of groin34,259C435B325200Malignant melanoma of buttock53,629C435B325500Malignant melanoma of perineum95,629C435B325.00Malignant melanoma of trunk (excluding scrotum)38,689C435B325z00Malignant melanoma of trunk, excluding scrotum, NOS45,760C435B325000Malignant melanoma of axilla49,814C435B326200Malignant melanoma of fore-arm45,755C436B326400Malignant melanoma of finger25,602C436B326300Malignant melanoma of hand62,475C436B326000Malignant melanoma of shoulder50,505C436B326500Malignant melanoma of thumb63,997C436B326z00Malignant melanoma of upper limb or shoulder NOS55,292C436B326100Malignant melanoma of upper arm54,685C436B326.00Malignant melanoma of upper limb and shoulder65,164C436B327500Malignant melanoma of ankle42,714C437B327700Malignant melanoma of foot41,490C437B327000Malignant melanoma of hip73,536C437B327100Malignant melanoma of thigh51,873C437B327800Malignant melanoma of toe36,899C437B327200Malignant melanoma of knee54,305C437B327.00Malignant melanoma of lower limb and hip46,255C437B327600Malignant melanoma of heel61,246C437B327300Malignant melanoma of popliteal fossa area39,878C437B327z00Malignant melanoma of lower limb or hip NOS64,327C437B327900Malignant melanoma of great toe53,369C437B327400Malignant melanoma of lower leg37,872C437B32y000Overlapping malignant melanoma of skin96,585C438B32z.00Malignant melanoma of skin NOS28,556C439Byu4100\[X\]malignant melanoma of skin, unspecified19,444C439B32..00Malignant melanoma of skin865C439B32y.00Malignant melanoma of other specified skin site42,153C439MyelomaB63z.00Immunoproliferative neoplasm or myeloma NOS43,450C889B630.12Myelomatosis15,211C900B630.00Multiple myeloma4944C900B630300Lambda light chain myeloma46,042C900B631.00Plasma cell leukaemia39,187C901B630100Solitary myeloma19,028C902B630200Plasmacytoma NOS21,329C902B630000Malignant plasma cell neoplasm, extramedullary plasmacytoma22,158C902OesophagusB100.00Malignant neoplasm of cervical oesophagus61,695C150B101.00Malignant neoplasm of thoracic oesophagus41,362C151B102.00Malignant neoplasm of abdominal oesophagus63,470C152B103.00Malignant neoplasm of upper third of oesophagus50,789C153B104.00Malignant neoplasm of middle third of oesophagus54,171C154B105.00Malignant neoplasm of lower third of oesophagus42,416C155B106.00Malignant neoplasm, overlapping lesion of oesophagus67,497C158B10y.00Malignant neoplasm of other specified part of oesophagus53,591C159B10z.00Malignant neoplasm of oesophagus NOS30,700C159B10z.11Oesophageal cancer4865C159B110111Malignant neoplasm of gastro-oesophageal junction94,278C160OvaryB440.00Malignant neoplasm of ovary7805C56B440.11Cancer of ovary1986C56B44..00Malignant neoplasm of ovary and other uterine adnexa19,141C578PancreasB162.00Malignant neoplasm of ampulla of vater10,949C241B170.00Malignant neoplasm of head of pancreas8771C250B171.00Malignant neoplasm of body of pancreas40,810C251B172.00Malignant neoplasm of tail of pancreas39,870C252B173.00Malignant neoplasm of pancreatic duct35,535C253B174.00Malignant neoplasm of islets of langerhans35,795C254B17y.00Malignant neoplasm of other specified sites of pancreas48,537C257B17yz00Malignant neoplasm of specified site of pancreas NOS95,783C257B175.00Malignant neoplasm, overlapping lesion of pancreas97,875C258B17y000Malignant neoplasm of ectopic pancreatic tissue96,635C259B17z.00Malignant neoplasm of pancreas NOS34,388C259ProstateB46..00Malignant neoplasm of prostate780C61StomachB110100Malignant neoplasm of cardio-oesophageal junction of stomach22,894C160B110z00Malignant neoplasm of cardia of stomach NOS37,859C160B110.00Malignant neoplasm of cardia of stomach32,022C160B113.00Malignant neoplasm of fundus of stomach32,362C161B114.00Malignant neoplasm of body of stomach43,572C162B112.00Malignant neoplasm of pyloric antrum of stomach19,318C163B111z00Malignant neoplasm of pylorus of stomach NOS59,092C164B111100Malignant neoplasm of pyloric canal of stomach41,215C164B111000Malignant neoplasm of prepylorus of stomach48,237C164B111.00Malignant neoplasm of pylorus of stomach21,620C164B115.00Malignant neoplasm of lesser curve of stomach unspecified42,193C165B116.00Malignant neoplasm of greater curve of stomach unspecified55,434C166B11y000Malignant neoplasm of anterior wall of stomach nec65,312C168B11y100Malignant neoplasm of posterior wall of stomach nec96,802C168B117.00Malignant neoplasm, overlapping lesion of stomach51,690C168B11yz00Malignant neoplasm of other specified site of stomach NOS65,372C169B11y.00Malignant neoplasm of other specified site of stomach55,019C169B11z.00Malignant neoplasm of stomach NOS14,800C169TestisB470200Seminoma of undescended testis7740C620B470.00Malignant neoplasm of undescended testis64,602C620B470300Teratoma of undescended testis36,325C620B470z00Malignant neoplasm of undescended testis NOS96,429C620B471z00Malignant neoplasm of descended testis NOS91,509C621B471000Seminoma of descended testis21,786C621B471100Teratoma of descended testis9476C621B471.00Malignant neoplasm of descended testis19,475C621B47z.00Malignant neoplasm of testis NOS38,510C629B47z.11Seminoma of testis2961C629B47z.12Teratoma of testis15,989C629B48y100Malignant neoplasm of tunica vaginalis47,668C637UterusB431000Malignant neoplasm of lower uterine segment59,097C540B431z00Malignant neoplasm of isthmus of uterine body NOS70,729C540B431.00Malignant neoplasm of isthmus of uterine body43,940C540B430211Malignant neoplasm of endometrium49,400C541B430200Malignant neoplasm of endometrium of corpus uteri2890C541B430300Malignant neoplasm of myometrium of corpus uteri45,793C542B430100Malignant neoplasm of fundus of corpus uteri68,155C543B432.00Malignant neoplasm of overlapping lesion of corpus uteri16,967C548B43z.00Malignant neoplasm of body of uterus NOS33,617C549B43y.00Malignant neoplasm of other site of uterine body31,608C549B430000Malignant neoplasm of cornu of corpus uteri72,723C549B430z00Malignant neoplasm of corpus uteri NOS45,490C549B43..00Malignant neoplasm of body of uterus7046C549B40..00Malignant neoplasm of uterus, part unspecified2744C55VulvalB451.00Malignant neoplasm of labia majora43,761C510B453.00Malignant neoplasm of clitoris53,910C512B45y000Malignant neoplasm of overlapping lesion of vulva27,617C518B454.00Malignant neoplasm of vulva unspecified4554C519B454.11Primary vulval cancer11,991C519B451z00Malignant neoplasm of labia majora NOS59,362C510B451000Malignant neoplasm of greater vestibular (Bartholin's) gland47,899C510B452.00Malignant neoplasm of labia minora58,061C511VaginalB450.00Malignant neoplasm of vagina37,328C52B450100Malignant neoplasm of vaginal vault10,698C52B450z00Malignant neoplasm of vagina NOS60,772C52

### Outcome---serious disease {#Sec21}

A library of candidate Read Codes for the most common serious diseases related to unexpected weight loss will be developed by combining two approaches: (i) review of the most frequent diagnostic codes entered in the clinical record within the period surrounding the unexpected weight loss code (descriptive study analysis section); (ii) review of the literature on causes of unexpected weight loss \[[@CR1], [@CR2]\]. A list of these candidate conditions will be reviewed independently by four co-investigators until consensus is reached on up to 20 serious diseases to be identified in the 24 months following the weight loss code.

### Covariates {#Sec22}

Data will also be extracted to explore the effect of the following factors which could independently impact the recording of weight and the occurrence of cancer:Personal characteristics---age, gender, ethnicity, smoking history, alcohol intake, family history of cancer, and IMD score recorded before the date of the weight loss code (index date).Co-morbidity---recorded before the index date (no time limit) or implied from the prescribing record at the index date.Other cancer symptoms and signs---using Read Codes for symptoms shown to have an independent association with cancer as described by NICE \[[@CR3]\]. These will be sought for 3 months before to 2 years after the index date.Results of basic cancer investigations used routinely in primary care: CxR, FBC, LFTs (inc. alkaline phosphatase), calcium, PSA, CA125, and inflammatory markers. These will be sought for 3 months before to 2 years after the index date.

Data/statistical analysis {#Sec23}
=========================

Aim 1: Descriptive study {#Sec24}
------------------------

To describe how often and when weight is recorded, we will request preliminary CPRD searches to identify all: (1) Read coded entries for weight loss and (2) quantitative weight measurements.

A subset of patients with weight measurements and unexpected weight loss codes will be used to develop a rule-based search strategy to categorise: (1) the clinical purpose (e.g. prevention, monitoring, diagnosis); (2) the related clinical condition (e.g. diabetes, heart failure, cancer). The GPs' subsequent actions will be described in terms of (1) investigations requested, (2) medications prescribed, and (3) referrals made. The search strategy will then be applied to the entire cohort of weight measurements and weight loss codes.

The most effective method to identify the reason for the weight entry and the subsequent action will be investigated. For example, codelists will be developed to capture the clinical purpose of the consultation associated with each weight measurement or weight loss code: health check codes will be used to identify prevention activity; chronic disease review codes will be used to identify monitoring. For associated clinical conditions, symptom and diagnostic codes entered at the same time as each weight measurement or weight loss code will be ascertained and frequency ranked for the entire descriptive study population. Initially, searches will be performed on the day of the weight entry, then a sensitivity analysis will be performed increasing the time window to ± 1 day of the weight entry, then 1 week, 1 month, and so on. This strategy will be repeated to identify investigation and referral codes following entry of the weight loss code.

Aim 2: Cohort analysis {#Sec25}
----------------------

### Cumulative incidence plots {#Sec26}

Cumulative incidence plots will be used to describe the probability of cancer or serious disease over time for those with and without weight loss. These will be assessed in aggregate and stratified by disease type, cancer stage, grade, tumour size, histology, and covariates.

Differences between those with and without weight loss will be assessed using the log-rank test.

### Multivariate Cox regression {#Sec27}

Cox regression will be used to estimate the adjusted hazard ratios (HR) for cancer or serious disease associated with weight loss recorded as a symptom.

The impact of choosing to restrict the follow-up period on the predictive value of weight loss will be explored by limiting the analysis by time period (0--6, 6--12, 12--18, and 18--24 months) and by including weight loss as a time dependent variable.

Age at index date, sex, ethnicity, IMD score, co-morbidity, smoking, and alcohol intake will be included, and the predictive value of other symptoms and investigations will be explored for (1) all cancers in aggregate, (2) cancer type, (3) by cancer stage, (4) by tumour size, (5) by grade of cancer and (6) serious disease type.

### Performance of diagnostic strategies {#Sec28}

To allow clinical guidance to be developed on how to rule-in or rule-out cancer or serious disease in adult patients (\> 18 years) with unexpected weight loss, diagnostic accuracy measures will be calculated for investigative strategies including those described in the literature including the subgroups of (1) gender and (2) age-group.

Plan for addressing confounding {#Sec29}
===============================

Aim 1: Descriptive study {#Sec30}
------------------------

Not required.

Aim 2: Cohort analysis {#Sec31}
----------------------

Patients who have conditions which might explain the weight loss (e.g. co-morbidities at the time of entry to the cohort or planned dieting) will be included and the impact of their inclusion assessed in multivariate and sensitivity analyses.

Patients with coded weight loss will be matched with patients without a weight loss code based on GP practice to account for systematic biases in coding between practices.

Age at index date, sex, IMD score, co-morbidity, smoking, and alcohol intake will be adjusted for in the multivariate modelling.

Plan for addressing missing data {#Sec32}
================================

Aim 1: Descriptive study {#Sec33}
------------------------

Weight is cited as a missing variable in CPRD as GPs do not routinely measure weight in NHS primary care \[[@CR8]\]. This descriptive analysis will add to our understanding of how often and when weight is recorded.

We will also describe the completeness of personal characteristics (as defined above) in relation to weight measurements and weight loss codes.

Aim 2: Cohort analysis {#Sec34}
----------------------

As measurements appear to be too infrequent to allow us to identify weight loss from serial weight measurement data, the cohort design will make best use of the coded weight loss information available in CPRD. For this reason, we do not intend to impute missing weight measurement values in the primary analysis, although the feasibility of using multiple imputation to address missing covariate values will be explored \[[@CR10]\].

Discussion {#Sec35}
==========

Within this section, we expand on the protocol as submitted to ISAC to elucidate decisions made about study design and to report developments made since commencing the study. We have incorporated and expanded upon the "Limitations of the study design, data sources and analytical methods" section of the original ISAC protocol.

Reliance on weight loss coding {#Sec36}
------------------------------

It appears from our preliminary searches that weight measurement is infrequent for the majority of patients in primary care, most likely initiated by a concern for underlying disease or existing chronic disease management. This is consistent with studies that acknowledge weight measurement as a source of missing data in NHS primary care records \[[@CR8]\]. Consequently, the detection of weight loss from serial weight measurements cannot be relied on as a method of defining weight loss. Our descriptive analysis is designed to identify whether a group of patients exists who undergo weight measurements more frequently, in which a future analysis involving serial weight measurements may be feasible. However, any subgroup is unlikely to be representative of the NHS primary care population. We have therefore chosen to focus on weight loss coding.

As with previous primary care studies using routinely collected data, an assumption will be made that the absence of a symptom code represents the absence of the symptom \[[@CR5], [@CR11]\]. This assumption has two major limitations: firstly, a coded entry is reliant on the patient visiting the GP and reporting the symptom; and secondly, that the GP chooses to enter the code in the record. Lack of the former would lead to an underestimation of the associated HR, and for the latter, selective recording of symptoms only deemed severe by the GP could lead to overestimated HRs. The latter is likely to differ by GP but cluster by GP practice, as GPs within the same practice are likely to have more similar approaches to coding. One method to address these limitations would be to analyse free-text entries to identify reported but uncoded symptoms, but at present CPRD does not allow requests for free-text entries and we will cite this as a weakness of our study \[[@CR12]\]. We decided to adjust for age and sex in multivariate analysis as the association between weight loss and cancer is not established for these variables.

### Sample size for cohort analysis {#Sec37}

Progress since the initial ISAC application has established that there are 148,000 patients eligible patients aged \> 18 years with an unexpected weight loss code as described in Appendix 1 (preliminary pilot work had suggested there was at least 30,000). This will therefore be the largest primary care CPRD cohort study using unexpected weight loss coding as the exposure variable. We originally calculated that only 2184 patients with weight loss are required to detect a hazard ratio of 2 at 99% power (0.05% alpha) using an enrolment ratio of 1:5. That is, a change in a cancer risk from a PPV of 1.5% in patients without weight loss to 3% in patients with weight loss. An alternative approach to estimating sample size is the number of Events Per Varaible in multivariate modelling. If 3% of patients with weight loss develop cancer the number of Events Per Variable will far exceed the minimum number of ten required for robust multivariate modelling. It is anticipated that the study will therefore have sufficient power for stratification by cancer type.

We aim to understand the association between weight loss and cancer in as much detail as the data permits. However, we accept it may not be possible to stratify for cancer stage or for other covariates with sufficient numbers remaining in each stratum. Cancer stage information is unsatisfactory in CPRD, which is why we have requested data linkage to the cancer registry (which will also be incomplete, but less so). Lifestyle covariates are non-essential for our main aim (to determine the predictive value of weight loss for cancer), and we will only perform analysis on sub-strata when numbers permit. Multiple imputation will be explored for these (and all other relevant missing) variables.

### Investigation and referral outcomes {#Sec38}

There remains uncertainty over the completeness of investigation and referral data until the descriptive analysis has been conducted. Data for laboratory investigations are likely to be more complete than data on radiological and endoscopic investigations, as laboratory investigations are commonly transmitted directly into the electronic health record from the laboratory whereas results for the other tests are not. Further linkage to the Diagnostic Imaging Dataset (for radiology activity) and Hospital Event Statistics (for endoscopy activity) may be necessary if these data are judged to be incomplete following the descriptive analysis, which would allow a formal comparison of data completeness to be conducted between these datasets and CPRD.

Implications {#Sec39}
============

A second cohort study using American primary care data is also in set-up to assess whether there is greater value in defining weight loss using serial weight measurements rather than a reliance on patient reported weight loss and a GP entered code. In particular, this study aims to establish whether weight loss detected using change in serial weight measurements leads to less advanced disease at diagnosis.

Together, these studies will provide the largest reported retrospective cohorts of primary care patients with unexpected weight loss used to understand the association between unexpected weight loss and serious disease including cancer. We hope our findings will directly inform international guidelines for the management of unexpected weight loss in primary care populations.

BMI

:   Body mass index

CPRD

:   Clinical Practice Research Datalink

IMD

:   Index of Multiple Deprivation

ISAC

:   Independent Scientific Advisory Group (to the CPRD)

Medcode

:   The CPRD unique code for the medical term selected by the GP

NCDR

:   National Cancer Data Repository

NICE

:   National Institute for Health and Care Excellence

Read code

:   The standard clinical terminology system used in general practice in the UK
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